Inoviv
Inoviv is dedicated to generating novel molecular insights to transform drug development and healthcare globally. They provide highly accurate, fully quantitative targeted biomarker analysis to accelerate the development of life-changing treatments, leveraging proprietary workflows and advanced proteomics solutions. Their mission includes expanding their proteomics offerings through collaborative studies, high-resolution discovery proteomics, and building translational value in therapeutic areas. They foster an open, respectful culture with flexible working arrangements, employee share options, and continuous professional development. Inoviv actively seeks talent across research, commercial, and operational functions to support their innovative biotech environment.
Industries
Nr. of Employees
small (1-50)
Products
Searchable pre-characterized protein catalog and custom panel selection
A searchable, pre-characterized protein database used to configure customizable multiplexed targeted proteomic panels for research and translational studies; supports target selection, panel submission workflows and subscription-based notifications for newly added proteins.
Validated multiplexed urine fibrosis biomarker panel
A validated multiplexed mass spectrometry assay for monitoring fibrosis-related protein biomarkers in urine and other matrices to support non-invasive monitoring and therapeutic evaluation in fibrotic diseases.
Immuno-enrichment plasma assay for neurodegeneration biomarkers
A quantitative, multiplexed immuno-enrichment mass spectrometry assay configured to measure low-level neurodegeneration-associated proteins in plasma with absolute quantification for clinical research use.
Searchable pre-characterized protein catalog and custom panel selection
A searchable, pre-characterized protein database used to configure customizable multiplexed targeted proteomic panels for research and translational studies; supports target selection, panel submission workflows and subscription-based notifications for newly added proteins.
Validated multiplexed urine fibrosis biomarker panel
A validated multiplexed mass spectrometry assay for monitoring fibrosis-related protein biomarkers in urine and other matrices to support non-invasive monitoring and therapeutic evaluation in fibrotic diseases.
Immuno-enrichment plasma assay for neurodegeneration biomarkers
A quantitative, multiplexed immuno-enrichment mass spectrometry assay configured to measure low-level neurodegeneration-associated proteins in plasma with absolute quantification for clinical research use.
Services
Consultation, discovery proteomics, targeted assay design, sample testing in inspected or certified laboratories, bioinformatics analysis, reporting, and validation support to translate biomarkers into clinically actionable assays.
Short discovery studies for single-matrix sample sets using high-resolution acquisition workflows (DIA or DDA) with delivery of raw data, processed outputs and interpretation, and options to progress to targeted assay development.
Design and validation of custom multiplexed targeted proteomic panels using a pre-characterized protein catalog and prioritized peptide selection to meet specific research or clinical endpoints.
On-site testing of clinical and research samples in inspected or certified laboratories with regulated documentation (chain-of-custody, QC) to support clinical study data and regulatory submissions.
Custom data processing pipelines, statistical analysis, visualization and quantitative reporting tailored to proteomics datasets for research interpretation and regulatory use.
Development and execution of immuno-capture mass spectrometry assays to enable absolute quantification of very low-abundance protein markers in plasma and other matrices in a multiplexed format, including workflows to support clinical trial monitoring.
Consultation, discovery proteomics, targeted assay design, sample testing in inspected or certified laboratories, bioinformatics analysis, reporting, and validation support to translate biomarkers into clinically actionable assays.
Short discovery studies for single-matrix sample sets using high-resolution acquisition workflows (DIA or DDA) with delivery of raw data, processed outputs and interpretation, and options to progress to targeted assay development.
Design and validation of custom multiplexed targeted proteomic panels using a pre-characterized protein catalog and prioritized peptide selection to meet specific research or clinical endpoints.
On-site testing of clinical and research samples in inspected or certified laboratories with regulated documentation (chain-of-custody, QC) to support clinical study data and regulatory submissions.
Custom data processing pipelines, statistical analysis, visualization and quantitative reporting tailored to proteomics datasets for research interpretation and regulatory use.
Development and execution of immuno-capture mass spectrometry assays to enable absolute quantification of very low-abundance protein markers in plasma and other matrices in a multiplexed format, including workflows to support clinical trial monitoring.
Expertise Areas
- Targeted quantitative proteomics assay development
- Discovery proteomics (DIA/DDA) and small-cohort proof-of-concept studies
- Biomarker discovery and translational bioanalysis
- Proteomics bioinformatics, statistical analysis and regulatory reporting
Key Technologies
- Liquid chromatography–tandem mass spectrometry (LC-MS/MS; MRM/PRM)
- Data-independent acquisition (DIA) and data-dependent acquisition (DDA)
- High-resolution mass spectrometry with ion mobility
- Immuno-enrichment coupled mass spectrometry (IP-MS)
News & Updates
Inoviv will be present at Booth #25 in San Diego, USA, to discuss biomarker strategies and proteomics solutions.
Inoviv launches FibroKey™, a mass spectrometry-based assay for non-invasive fibrosis biomarker monitoring.
Inoviv will be present at Booth #25 in San Diego, USA, to discuss biomarker strategies and proteomics solutions.
Inoviv launches FibroKey™, a mass spectrometry-based assay for non-invasive fibrosis biomarker monitoring.